Security National Bank of Sioux City Iowa IA increased its stake in shares of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 6.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,510 shares of the financial services provider’s stock after acquiring an additional 614 shares during the quarter. Security National Bank of Sioux City Iowa IA’s holdings in iShares Nasdaq Biotechnology ETF were worth $1,160,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Paloma Partners Management Co lifted its stake in shares of iShares Nasdaq Biotechnology ETF by 1,643.3% in the second quarter. Paloma Partners Management Co now owns 323,373 shares of the financial services provider’s stock valued at $35,513,000 after buying an additional 304,824 shares in the last quarter. Credit Suisse AG lifted its stake in shares of iShares Nasdaq Biotechnology ETF by 1,228.8% in the third quarter. Credit Suisse AG now owns 224,782 shares of the financial services provider’s stock valued at $27,410,000 after buying an additional 207,866 shares in the last quarter. Commerzbank Aktiengesellschaft FI lifted its stake in shares of iShares Nasdaq Biotechnology ETF by 54.0% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 585,506 shares of the financial services provider’s stock valued at $64,300,000 after buying an additional 205,200 shares in the last quarter. Alliancebernstein L.P. lifted its stake in shares of iShares Nasdaq Biotechnology ETF by 36.2% in the third quarter. Alliancebernstein L.P. now owns 737,179 shares of the financial services provider’s stock valued at $89,892,000 after buying an additional 195,746 shares in the last quarter. Finally, Aviance Capital Management LLC lifted its stake in shares of iShares Nasdaq Biotechnology ETF by 730.2% in the third quarter. Aviance Capital Management LLC now owns 147,849 shares of the financial services provider’s stock valued at $18,029,000 after buying an additional 130,040 shares in the last quarter. 63.65% of the stock is currently owned by institutional investors and hedge funds.

Shares of iShares Nasdaq Biotechnology ETF stock traded down $1.17 during trading hours on Thursday, reaching $105.54. The company’s stock had a trading volume of 38,427 shares, compared to its average volume of 1,779,652. iShares Nasdaq Biotechnology ETF has a one year low of $100.22 and a one year high of $122.97.

WARNING: “iShares Nasdaq Biotechnology ETF (IBB) Shares Bought by Security National Bank of Sioux City Iowa IA” was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.watchlistnews.com/ishares-nasdaq-biotechnology-etf-ibb-shares-bought-by-security-national-bank-of-sioux-city-iowa-ia/2665184.html.

iShares Nasdaq Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Featured Article: What does relative strength index mean?

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.